AN2 Therapeutics (NASDAQ:ANTX) just reported results for the first quarter of 2024.
- AN2 Therapeutics reported earnings per share of -56 cents. This was above the analyst estimate for EPS of -62 cents.
- The company did not report any revenue for the quarter.